3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Transitional Cell
24
Urinary Bladder Neoplasms
22
Ureteral Neoplasms
8
Urologic Neoplasms
4
Urethral Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Neoplasm Metastasis
3
Peripheral Nervous System Diseases
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Muscle-invasive Bladder Cancer
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
Cyclophosphamide
135
aldesleukin
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
68
dabrafenib
65
fludarabine phosphate
62
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
Magnetic Resonance Spectroscopy
33
cobimetinib
32
Specimen Handling
31
Introns
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
enfortumab vedotin
×
Clear all
NCT06906822
2025-09-18
PlugIN
Grupo Español Multidisciplinar de Melanoma
Phase 2
Recruiting
60 enrolled